MAPT and Alzheimer disease: The finding that [18F]flortaucipir visual reads could reliably detect tauopathies in Braak stages V and VI (4) (widespread neocortical tau pathology) led to the approval of [18F]flortaucipir by the Food and Drug Administration as a biomarker for supporting a diagnosis of AD (8).